SCHEDULE 13G/A: Bain Capital Discloses 9.99% Stake in Cabaletta Bio

Bain Capital Life Sciences Opportunities III, LP has disclosed a 9.99% beneficial ownership stake in Cabaletta Bio, Inc., comprising common stock and warrants.

Summary

• Bain Capital Life Sciences Opportunities III, LP (the "Reporting Person") has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Cabaletta Bio, Inc.
• As of June 30, 2025, the Reporting Person beneficially owned 9,677,125 shares of Cabaletta Bio's Common Stock.
• This ownership represents 9.99% of the total outstanding shares of Common Stock.
• The holdings include 4,260,888 shares of Common Stock, a warrant to purchase up to 7,500,000 shares, and a pre-funded warrant to purchase up to 6,000,000 shares.
• A "Beneficial Ownership Blocker" prevents the Reporting Person from exercising warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
• The percentage is calculated based on 91,451,899 shares outstanding as of June 30, 2025, plus 5,416,237 shares issuable upon partial exercise of warrants, reflecting the blocker.
• The Reporting Person holds shared voting and dispositive power over all 9,677,125 beneficially owned shares.
• The securities were not acquired for the purpose of changing or influencing the control of Cabaletta Bio, Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. The continued significant stake by a major investor is generally neutral to slightly positive.

Positives

• A significant institutional investor, Bain Capital Life Sciences Opportunities III, LP, maintains a substantial stake in Cabaletta Bio, indicating continued confidence in the company's long-term prospects.
• The disclosure of a 9.99% stake by a reputable life sciences fund can be viewed positively by the market, potentially attracting further investor interest.

Negatives

• The "Beneficial Ownership Blocker" limits Bain Capital's ability to increase its percentage ownership beyond 9.99% through warrant exercise, potentially capping its influence or upside from these instruments.

Risks

• The Beneficial Ownership Blocker restricts the Reporting Person's ability to fully exercise its warrants if doing so would cause its beneficial ownership to exceed 9.99% of the total outstanding shares.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Cabaletta Bio, Inc. It solely reflects the current beneficial ownership position of Bain Capital Life Sciences Opportunities III, LP.

Industry Context

This filing highlights continued investment by specialized life sciences funds, such as Bain Capital, in biotechnology companies like Cabaletta Bio. Such investments are common in the biotech sector, where significant capital is often required for research, development, and clinical trials. A substantial stake from a prominent investor can signal market confidence in the company's pipeline and strategic direction.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Bain Capital may influence market perception and potentially investor confidence in Cabaletta Bio.
• Company Management: Awareness of a large, active investor on the cap table may influence strategic decisions, though the filing states the stake is not for control purposes.

Key Dates

Keywords

Cabaletta Bio, Bain Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Biotechnology, Institutional Investor, Equity Stake